Interius BioTherapeutics

Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.  Interius’ lead programs are initially focused on treating hematologic malignancies by leveraging their proprietary platform to generate chimeric antigen receptor (CAR) T cells directly in vivo.